Specifically, in EGFR mutations, erlotinib was the first FDA-approved tyrosine kinase inhibitor (TKI) for NSCLC in 2013 for first-line treatment in metastatic EGFR-mutated NSCLC based on erlotinib having significant PFS benefit compared to chemotherapy [61]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.